GlassScriptPhysician profile
Cristin Parker Howe
NPI 1184696247
$5,176.77
in general payments reported to CMS, 2019-2025
24 companies · $681 in 2025
The $681 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $396 · 2021: $696 · 2022: $838 · 2023: $903 · 2024: $875 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,458.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,015.30 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $766.76 | 2019-2025 | |
| Abbvie INC. | $555.55 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $464.24 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.10 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $313.87 | 2019-2025 | Zerbaxa, Dificid, Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.82 | 2020-2025 | Xifaxan |
| Gilead Sciences, INC. | $236.11 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $191.12 | 2019-2024 | Lokelma |
| Alexion Pharmaceuticals, INC. | $151.47 | 2019-2025 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $116.17 | 2019 | |
| Allergan, INC. | $115.27 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $100.48 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $92.65 | 2019 | |
| Sk Life Science, INC. | $89.29 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $63.09 | 2019-2024 | Rybelsus, Ozempic |
| Cvrx, INC. | $59.12 | 2022-2024 | Barostim Neo System |
| Paratek Pharmaceuticals, INC. | $41.57 | 2022-2023 | Nuzyra |
| Philips North America LLC | $33.74 | 2021-2023 | |
| Electromed, INC. | $29.97 | 2023 | Smartvest |
| Boston Scientific Corporation | $29.38 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.13 | 2025 | Lifevest |
| Abbott Laboratories | $23.47 | 2024 | Mitraclip |
| Bioxcel Therapeutics, INC. | $23.10 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristin Howe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.